TVAX Biomedical Announces Receipt of $2 Million FDA Orphan Products Grant for Glioblastoma Study
yahoo.com
finance
2022-10-18 14:07:00

Image

Patient with recurrent high-grade glioma treated with TVAX Immunotherapy

Patient with recurrent high-grade glioma treated with TVAX Immunotherapy

OLATHE, Kan., Oct. 18, 2022 (GLOBE NEWSWIRE) -- TVAX Biomedical (TVAX) is a cancer immunotherapy company that is moving into its pivotal glioblastoma study for FDA regulatory approval. In September 2022, TVAX Biomedical received an approximately $2 million 4-year grant from the FDA Office of Orphan Products for its planned glioblastoma study. TVAX ImmunotherapyÂ® could fundamentally change the way cancer is treated as T cells can kill all cancer cells, including cancer stem cells, without the toxicity of current treatments.
